Johnson & Johnson unit Janssen Pharmaceuticals' Zytiga, or abiraterone acetate, in combination with prednisone was approved by the FDA as a treatment for patients with metastatic high-risk castration-sensitive prostate cancer. The drug, which was previously approved for patients with late-stage prostate cancer, reduced the risk of death by 38% versus placebo use in a late-stage study for CSPC patients.
Janssen's Zytiga approved for castration-sensitive prostate cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.